Ingemar Lagerlöf

Survival and treatment related toxicity in classical Hodgkin lymphoma

Lagerlöf, Ingemar

2023

• Download full text (pdf) of Survival and treatment related toxicity in classical Hodgkin lymphoma

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.

Part of Journal of Clinical Oncology, p. 1487-1496, 2022

• DOI for Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
• Download full text (pdf) of Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Wahlin, Bjoern Engelbrekt; Övergaard, Ninja; Peterson, Stefan; Digkas, Evangelos et al.

Part of eJHaem, p. 400-412, 2021

• DOI for Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
• Download full text (pdf) of Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Lagerlöf, Ingemar; Holte, Harald; Glimelius, Ingrid; Björkholm, Magnus et al.

Part of British Journal of Haematology, p. 685-691, 2020

• DOI for No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance

Harwood, Matthew; Hodges, Georgina; Tan, Xuan; Cheah, Chan Y. et al.

Part of Leukemia and Lymphoma, p. 3412-3416, 2020

• DOI for Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.

Part of Journal of Clinical Oncology, p. 1487-1496, 2022

• DOI for Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
• Download full text (pdf) of Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Wahlin, Bjoern Engelbrekt; Övergaard, Ninja; Peterson, Stefan; Digkas, Evangelos et al.

Part of eJHaem, p. 400-412, 2021

• DOI for Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
• Download full text (pdf) of Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Lagerlöf, Ingemar; Holte, Harald; Glimelius, Ingrid; Björkholm, Magnus et al.

Part of British Journal of Haematology, p. 685-691, 2020

• DOI for No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance

Harwood, Matthew; Hodges, Georgina; Tan, Xuan; Cheah, Chan Y. et al.

Part of Leukemia and Lymphoma, p. 3412-3416, 2020

• DOI for Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance

Second cancer is the leading cause of death, with no increase of cardiovascular deaths, after combined modality Hodgkin lymphoma treatment

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.

Survival and treatment related toxicity in classical Hodgkin lymphoma

Lagerlöf, Ingemar

2023

• Download full text (pdf) of Survival and treatment related toxicity in classical Hodgkin lymphoma

Real-life data on morbidity and cause-specific mortality after combined modality treatment for Hodgkin lymphoma 2006-2015.

Lagerlöf, Ingemar; Wikman, Per; Enblad, Gunilla; Goldkuhl, Christina et al.